CLAIMS

1. Use of a therapeutically effective amount of a humanized monoclonal anti-calcitonin gene-related peptide (CGRP) antagonist antibody in the manufacture of a medicament for treating or preventing headache in a subject, wherein:

i) the subject has been earlier treated with a first dose of said humanized monoclonal anti-calcitonin gene-related peptide (CGRP) antagonist antibody, which subject has a < 50% reduction from baseline in Monthly Migraine Days ("MMD response") after said first dose, and

ii) wherein said medicament is to be administered to the subject as a second dose,

wherein said humanized monoclonal anti-calcitonin gene-related peptide (CGRP) antagonist antibody in (i) and (ii) comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 6 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 12.

2. Use of a therapeutically effective amount of a humanized monoclonal anti-calcitonin gene-related peptide (CGRP) antagonist antibody in the manufacture of a medicament for treating or preventing headache in a subject, wherein:

i) the subject has been treated with a first dose of said humanized monoclonal anti-calcitonin gene-related peptide (CGRP) antagonist antibody and wherein it is to be determined whether said subject has a < 50% reduction from baseline in Monthly Migraine Days ("MMD response") after said first dose, and

ii) wherein said medicament is to be administered as a second dose of said humanized monoclonal anti-calcitonin gene-related peptide (CGRP) antagonist antibody, if the subject has been determined to have < 50% reduction from baseline in MMD response after said first dose,

wherein said humanized monoclonal anti-calcitonin gene-related peptide (CGRP) antagonist antibody comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 6 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 12.

3. The use **according to claim 1 or 2**, wherein after the first dose of said CGRP antagonist antibody the subject has a less than 45%, less than 35%, less than 25%, less than 15%, less than 5% or not responding (≈0%) MMD response.

4. The use **according to claim 1, 2 or 3**, wherein the subject has migraine or cluster headache.

5. The use **according to claim 1, 2, 3 or 4**, wherein said headache is episodic migraine, chronic migraine, episodic cluster headache or chronic cluster headache.

6. The use **according to claim 4 or 5**, wherein the subject experiences migraines with aura.

7. The use **according to claim 4 or 5**, wherein the subject experiences migraines without aura.

8. The use **according to any one of the preceding claims**, wherein the subject in step i) **of claim 1 or 2** has only received one dose of said humanized monoclonal anti-calcitonin gene-related peptide (CGRP) antagonist antibody.

9. The use **according to any one of the preceding claims**, wherein said subject received the same dose in step i) and step ii) or a different dose in step i) and step ii).

10. The use **according to any one of the preceding claims,** wherein the monoclonal antibody is to be administered at a dose of 100 mg to 500 mg in step i) and a dose of 100 mg to 500 mg is to be administered in step ii) of claim 1 or 2.

11. The use **according to any one of the preceding claims**, wherein the monoclonal antibody is to be administered at a dose of about 100 mg, about 300 mg or about 400 mg in step i) and about 100 mg, about 300 mg or about 400 mg is to be administered in step ii) of claim 1 or 2.

12. The use **according to any one of the preceding claims**, wherein the monoclonal antibody is to be administered about once every 3 months.

13. The use according **to any one of the preceding claims**, wherein said selected subject did not experience any MMD reduction after their first dose of said humanized monoclonal anti-calcitonin gene-related peptide (CGRP) antagonist antibody.

14. The use **according to any one of the preceding claims**, wherein said selected subject did not experience a ≥50% MMD response to their first dose of said humanized monoclonal anti-calcitonin gene-related peptide (CGRP) antagonist antibody within 1 to 12 weeks after the first dose.

15. The use **according to any one of the preceding claims**, wherein said selected subject did not experience a ≥50% MMD response to their first dose of said humanized monoclonal anti-calcitonin gene-related peptide (CGRP) antagonist antibody within 1 to 4 weeks after the first dose.

16. The use **according to any one of the preceding claims,** wherein said selected subject did not experience a ≥50% MMD response to their first dose of said humanized monoclonal anti-calcitonin gene-related peptide (CGRP) antagonist antibody within 1 to 2 weeks after the first dose.

17. The use **according to any one of the preceding claims**, wherein if the subject has a ≥ 50% MMD response after administration of the second dose, the subject is to be administered a third dose of said humanized monoclonal anti-CGRP antagonist antibody, wherein the third dose of said

humanized monoclonal anti-CGRP antagonist antibody optionally is the same or greater than the first or second antibody dose amounts.

18. The use according to **any one of the preceding claims**, wherein if the subject does not have a ≥ 50% MMD response after administration of the second dose, the subject is to be administered a third dose of said humanized monoclonal anti-CGRP antagonist antibody, wherein the dose amount of said third dose of humanized monoclonal anti-CGRP antagonist antibody optionally is greater than the first or second antibody dose amounts.

19. The use **according to any one of the preceding claims**, wherein if the subject does not have a ≥ 50% MMD response after administration of the second dose, then the subject is not administered a third dose of said humanized monoclonal anti-calcitonin gene-related peptide (CGRP) antagonist antibody.